Transarterial Chemoembolization: How It Works, Results and What to Expect

Transarterial chemoembolization, often called TACE, is a minimally invasive treatment mainly used for liver tumors that cannot be removed safely with surgery. It delivers anticancer medicine directly into arteries feeding a tumor and then reduces that tumor’s blood supply, helping control disease while limiting exposure to the rest of the body.

Overview: what is transarterial chemoembolization?

Transarterial chemoembolization (TACE) is a catheter-based cancer treatment used primarily for tumors in the liver. A specialist in interventional radiology guides a thin tube through an artery, usually starting in the groin or wrist, into the arteries that supply the tumor. Chemotherapy is delivered directly to the target area, followed by tiny particles or material that slows or blocks blood flow to the tumor.

Because many liver tumors receive much of their blood supply from the hepatic artery, while healthy liver tissue receives much of its blood from the portal vein, TACE can target the tumor more selectively than chemotherapy given through a vein. The treatment is commonly used for hepatocellular carcinoma, also called HCC, and may sometimes be considered for certain liver metastases or other liver tumors in selected circumstances.

TACE is usually part of an individualized treatment plan created by liver specialists, medical oncologists, surgical oncologists, radiation oncologists, and interventional radiologists. Its goals may include controlling tumor growth, relieving tumor-related symptoms in some people, reducing tumor burden, or helping maintain eligibility for a future liver transplant or another local treatment.

How TACE works and who may be a candidate

TACE works through two complementary effects. First, a high concentration of chemotherapy is placed into the artery feeding the tumor. Second, embolic material blocks or markedly reduces that artery’s flow. This can keep the medicine near the tumor longer and deprive cancer cells of oxygen and nutrients.

Conventional TACE commonly uses a chemotherapy mixture with an oily contrast material, followed by embolic particles. Drug-eluting bead TACE uses small beads that release chemotherapy gradually while also blocking blood flow. The most appropriate approach depends on the tumor pattern, arterial anatomy, prior treatments, liver function, and the team’s clinical judgment.

People may be considered for TACE when liver cancer is confined mainly to the liver and surgery, ablation, or transplantation is not immediately suitable. Candidates often have a reasonable level of liver function and blood flow through the main portal vein. TACE may be less appropriate when liver function is severely reduced, there is uncontrolled infection, significant kidney problems, certain blood-clotting concerns, or extensive tumor involvement. A careful assessment is needed because treatment decisions are highly individual.

• Imaging is used to define the number, size, and location of tumors.
• Blood tests assess liver function, kidney function, blood counts, and clotting.
• The team reviews medications, allergies, previous treatments, and overall fitness for the procedure.

What happens during the TACE procedure?

Before TACE, the care team explains how to prepare. This may include instructions about fasting, diabetes medicines, blood thinners, and arranging for someone to accompany the patient home. The procedure is usually performed in an angiography suite with X-ray guidance. Sedation and pain-relieving medicine are often used; some patients may require anesthesia depending on their needs and the planned treatment.

After cleaning and numbing the skin, the interventional radiologist inserts a small catheter into an artery, commonly in the groin or wrist. Using live X-ray imaging and contrast dye, the specialist advances the catheter through blood vessels to the arteries supplying the liver tumor. An angiogram maps the blood supply, allowing the treatment to be delivered as selectively as possible.

The chemotherapy and embolic material are then released into the selected vessel or vessels. The catheter is removed, and pressure or a closure device is used at the access site. Procedure time varies with the number of tumors and complexity of the blood vessels, but patients should expect several hours for preparation, treatment, and observation.

For patients needing a local liver-directed approach, transarterial chemoembolization treatment may be discussed alongside surgery, thermal ablation, systemic therapy, radiation-based treatment, or transplant evaluation. The recommendation is based on the whole clinical picture rather than on tumor size alone.

Recovery timeline, benefits and possible risks

Many people stay in hospital overnight after TACE, while others may need longer monitoring depending on liver function, symptoms, and the extent of treatment. Mild to moderate tiredness, reduced appetite, nausea, low-grade fever, and discomfort in the upper right abdomen can occur during the first few days. This group of temporary symptoms is often called post-embolization syndrome.

Recovery differs from person to person. Most patients are advised to rest, drink fluids as directed, take prescribed medicines, and avoid heavy lifting for a short period after an arterial access procedure. The care team provides specific instructions about wound care, driving, work, activity, and when to restart regular medicines.

The potential benefit of TACE is local tumor control without open surgery. It may shrink or devitalize tumors, delay progression in suitable patients, and sometimes serve as a bridge to liver transplantation. It does not remove every cancer cell in all cases, and additional TACE sessions or other therapies may be needed.

Possible complications include pain, fever, nausea, bleeding or bruising at the catheter site, contrast reactions, infection, damage to healthy liver tissue, blood-vessel injury, and worsening liver function. Rarely, embolic material can affect tissue outside the intended area. The care team takes steps to reduce these risks and monitors patients closely before and after treatment.

How is response assessed after TACE?

TACE does not usually produce an immediate visible result. Follow-up contrast-enhanced CT or MRI is commonly arranged several weeks after treatment to assess whether the treated tumor still has active blood flow or enhancement. Blood tests, including liver function tests and selected tumor markers when appropriate, also help guide care.

Doctors assess response by looking at viable, or active, tumor tissue rather than size alone. A tumor can remain similar in size after treatment but show little or no remaining blood supply, which may indicate a good local response. Conversely, persistent or new enhancement may suggest that further treatment is needed.

Follow-up appointments are also important for identifying new tumors elsewhere in the liver, monitoring underlying liver disease, and considering other options. Depending on the situation, these may include radiofrequency ablation, systemic anticancer medicines, radiation therapy, surgery, or transplant assessment.

What is the success rate of transarterial chemoembolization?

There is no single success rate for transarterial chemoembolization because “success” can mean different things: reduction in active tumor tissue, disease control, symptom improvement, eligibility for another treatment, or survival. Results vary substantially according to the stage and biology of the cancer, the number and location of tumors, liver reserve, portal-vein blood flow, and whether other treatments are used.

For carefully selected people with intermediate-stage hepatocellular carcinoma and preserved liver function, TACE can provide meaningful local disease control. Some tumors show substantial loss of blood supply after treatment, while others respond less strongly or regrow over time. Repeat treatment is common when it remains safe and clinically appropriate.

Patients can ask their specialist what outcome is realistic in their individual situation. A multidisciplinary review is particularly helpful because it considers whether TACE is the best first option, whether it should be combined with another approach, and when a change in treatment strategy may be advisable.

How long does it take for TACE to work?

TACE starts affecting the tumor’s blood supply during the procedure, but its clinical effect is evaluated over time. Symptoms related to the procedure may settle over days to weeks, while imaging is generally performed several weeks later to allow the treated area to stabilize and to assess remaining viable tumor.

In some patients, the first scan shows a strong response after one treatment. Others require more than one session, often spaced apart to allow the liver to recover and to reassess the target areas. The exact timing of scans and possible repeat TACE depends on liver tests, recovery, imaging findings, and the treatment plan.

It is important not to judge effectiveness solely by how a person feels after treatment. Follow-up imaging interpreted by the liver cancer team is the most reliable way to determine whether the tumor has responded and whether further care is needed.

How long does TACE extend life expectancy?

TACE may help some appropriately selected patients live longer than they would with supportive care alone, but it is not possible to predict how much it will extend life for an individual person. Survival depends on the cancer stage, liver function, underlying cirrhosis or hepatitis, response to treatment, overall health, and access to additional treatments when needed.

For many people, the purpose of TACE is to control cancer in the liver and preserve treatment options. It may be used repeatedly when benefits continue to outweigh risks, or it may be followed by a different therapy if the cancer no longer responds or liver function changes.

A treating oncologist or liver specialist can discuss prognosis in a way that reflects the person’s specific test results and treatment goals. Honest conversations about likely benefits, side effects, quality of life, and alternatives support informed, patient-centered decisions.

How successful is TACE for liver cancer?

TACE is an established treatment for selected patients with liver cancer, especially hepatocellular carcinoma that is not suitable for curative surgery or ablation but remains predominantly within the liver. It is often most useful for intermediate-stage disease, although it can also be used in other settings, such as downstaging or bridging to transplantation, when the multidisciplinary team considers it appropriate.

Its success for liver cancer is best understood as disease control rather than a universal cure. TACE may destroy or substantially reduce viable tumor tissue in treated areas, but liver cancer can recur or new tumors can develop, particularly when chronic liver disease remains present. Continued surveillance is therefore essential.

At Acibadem International, multidisciplinary specialists in JCI-accredited hospitals evaluate and treat liver tumors for international patients, coordinating interventional radiology with oncology, hepatology, surgery, and transplant services when appropriate.

When to seek medical care

Anyone with a known liver tumor should keep scheduled oncology and liver-care appointments, even if they feel well. New symptoms do not always mean the cancer has changed, but prompt medical advice can help identify treatable problems. Patients considering TACE should discuss all current medicines, allergies, kidney disease, liver symptoms, and previous cancer treatments with their clinical team.

After TACE, the treating team should be contacted urgently for fever that is persistent or high, worsening abdominal pain, repeated vomiting, increasing jaundice, confusion, severe weakness, shortness of breath, heavy bleeding, or redness and swelling at the catheter site. Emergency care is appropriate for severe symptoms, fainting, chest pain, or signs of a serious allergic reaction.

Regular liver cancer surveillance and management of underlying liver disease remain important after any local treatment. Avoiding alcohol when advised, taking medicines as prescribed, attending imaging appointments, and asking early about new symptoms can support safer recovery and ongoing care.

Frequently asked questions

Is transarterial chemoembolization the same as chemotherapy?

No. Standard chemotherapy circulates through the bloodstream and can reach cancer cells throughout the body. TACE delivers chemotherapy directly into arteries feeding a liver tumor and combines it with an embolization step that reduces tumor blood flow.

Is TACE a cure for liver cancer?

TACE is not usually considered a curative treatment on its own. It is commonly used to control liver tumors, reduce active tumor tissue, or support another treatment plan, such as transplant evaluation or additional local therapy.

Will TACE make a patient lose their hair?

Hair loss is generally less likely with TACE than with chemotherapy given throughout the body because the medicine is delivered locally. However, side effects vary with the medicines used, liver function, and the individual patient, so the treating team can explain expected effects.

How many TACE treatments are needed?

Some people need one TACE session, while others may need repeat procedures if imaging shows remaining active tumor or new treatable lesions. The decision depends on response, liver recovery, symptoms, and whether the expected benefit continues to outweigh risks.

Can TACE be performed if a patient has cirrhosis?

Yes, TACE may be considered in some people with cirrhosis, since cirrhosis commonly coexists with hepatocellular carcinoma. However, liver reserve must be assessed carefully because reduced liver function can increase the risk of complications after embolization.

What should a patient ask before TACE?

Useful questions include the goal of treatment, expected benefits, alternatives, likely recovery time, possible complications, and the planned follow-up schedule. Patients may also ask how their liver function and tumor pattern affect whether repeat TACE or another treatment may be needed.

References

• American Cancer Society
• National Cancer Institute
• European Society for Medical Oncology
• American Association for the Study of Liver Diseases
• Society of Interventional Radiology

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.